華海清科(688120.SH):2024年度淨利潤10.2億元,同比增長40.99%
格隆匯2月27日丨華海清科(688120.SH)公佈2024年度業績快報,報告期內,實現營業總收入34.14億元,同比增長36.12%;實現歸屬於母公司所有者的淨利潤10.2億元,同比增長40.99%;實現歸屬於母公司所有者的扣除非經常性損益的淨利潤8.54億元,同比增長40.39%。
報告期內,公司憑藉產品技術優勢,成功把握市場機遇,CMP產品市場佔有率和銷售規模持續提高,並且公司持續加大研發投入和生產能力建設,增強企業核心競爭力,新產品研發和銷售進展順利,減薄裝備、清洗裝備、晶圓再生、CDS和SDS等初顯市場成效,提升了公司營收和盈利規模。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.